Study Examines Genetics Impact on Statin Disposition and Response

Title

Study Examines Genetics Impact on Statin Disposition and Response

Files

Download Transcript, Episode 38 (81 KB)

Loading...

Media is loading
 

Document Type

Podcast

Hosts

Michael Smith

Featured Speaker

Jonathan B. Wagner, DO

Length of Episode

12:42

Description

Based on guidelines from the American Academy of Pediatrics (AAP), approximately 0.8 percent of adolescents 12 to 17 years old with dyslipidemia may qualify for pharmacological treatment.

That translates into approximately 200,000 adolescents who could be eligible for statin therapy.

With the increasing prevalence of overweight children, the incidence of clinically diagnosed coronary artery disease in young to middle-aged adults is expected to increase by 5 to 16 percent over the next two decades.

Jon Wagner, DO, is here to discuss how he is leading a research study looking at the liver specific protein transporter, OATP1B1, which is the major transporter of statins from the blood to the liver to better understand how children’s bodies distribute statins in the body.

Click here to stream the podcast episode.

Publication Date

1-14-2016

Study Examines Genetics Impact on Statin Disposition and Response

Share

COinS